Paul Elvin

1.9k total citations
47 papers, 1.3k citations indexed

About

Paul Elvin is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Paul Elvin has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 17 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Paul Elvin's work include PI3K/AKT/mTOR signaling in cancer (7 papers), Cell Adhesion Molecules Research (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Paul Elvin is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (7 papers), Cell Adhesion Molecules Research (6 papers) and Lung Cancer Treatments and Mutations (4 papers). Paul Elvin collaborates with scholars based in United Kingdom, United States and France. Paul Elvin's co-authors include Clive W. Evans, Alexander Graham, Tim P. Green, Andrew Cassidy, Jean Paul Thiery, François Radvanyi, Isabelle Bernard‐Pierrot, Barry R. Davies, Amanda L. Garner and Vivien N. Jacobs and has published in prestigious journals such as Nucleic Acids Research, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Paul Elvin

45 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Elvin United Kingdom 20 732 391 230 147 138 47 1.3k
Steven A. Enkemann United States 18 783 1.1× 414 1.1× 246 1.1× 121 0.8× 65 0.5× 31 1.3k
Dorina Gui United States 23 862 1.2× 345 0.9× 243 1.1× 166 1.1× 115 0.8× 52 1.7k
Hoanh Tran United States 16 1.1k 1.5× 282 0.7× 225 1.0× 88 0.6× 102 0.7× 21 1.5k
Pjotr Knyazev Germany 21 1.0k 1.4× 664 1.7× 226 1.0× 125 0.9× 158 1.1× 30 1.9k
Maria Zajac‐Kaye United States 28 1.2k 1.6× 833 2.1× 276 1.2× 175 1.2× 206 1.5× 65 1.9k
Sachi Horibata United States 16 838 1.1× 477 1.2× 281 1.2× 123 0.8× 92 0.7× 31 1.6k
Mei Dong China 18 1.2k 1.7× 539 1.4× 332 1.4× 159 1.1× 94 0.7× 36 1.7k
Mariana Nacht United States 17 1.0k 1.4× 441 1.1× 250 1.1× 133 0.9× 41 0.3× 27 1.5k
Wendy S. Halsey United States 13 536 0.7× 371 0.9× 105 0.5× 135 0.9× 80 0.6× 19 1.3k
Randolph S. Watnick United States 16 788 1.1× 662 1.7× 398 1.7× 161 1.1× 72 0.5× 27 1.4k

Countries citing papers authored by Paul Elvin

Since Specialization
Citations

This map shows the geographic impact of Paul Elvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Elvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Elvin more than expected).

Fields of papers citing papers by Paul Elvin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Elvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Elvin. The network helps show where Paul Elvin may publish in the future.

Co-authorship network of co-authors of Paul Elvin

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Elvin. A scholar is included among the top collaborators of Paul Elvin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Elvin. Paul Elvin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Min, Ahrum, Hyemin Jang, Seongyeong Kim, et al.. (2018). Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. Molecular Cancer Therapeutics. 17(12). 2507–2518. 15 indexed citations
2.
Kopetz, Scott, Van K. Morris, Nila U. Parikh, et al.. (2014). Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer. 14(1). 660–660. 15 indexed citations
3.
Im, Seock‐Ah, Do‐Youn Oh, Paul Elvin, et al.. (2012). Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer. Molecular Cancer Therapeutics. 12(1). 16–26. 50 indexed citations
4.
Boult, Jessica K.R., Yann Jamin, Vivien N. Jacobs, et al.. (2012). False-negative MRI biomarkers of tumour response to targeted cancer therapeutics. British Journal of Cancer. 106(12). 1960–1966. 7 indexed citations
5.
Baselga, José, Andrés Cervantes, Erika Martinelli, et al.. (2010). Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research. 16(19). 4876–4883. 95 indexed citations
6.
Jürgensmeier, Juliane M., Jane Kendrew, Rajesh Odedra, et al.. (2010). Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo. Cancer Research. 70(8_Supplement). 1372–1372. 2 indexed citations
7.
Ammer, Amanda G., Laura C. Kelley, Karen E. Hayes, et al.. (2009). Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. Journal of Cancer Science & Therapy. 1(2). 52–61. 62 indexed citations
8.
Green, Tim P., Jon Curwen, Vivien N. Jacobs, et al.. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology. 3(3). 248–261. 176 indexed citations
9.
Renshaw, Lorna, Vivien N. Jacobs, Michael Fennell, et al.. (2008). Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment. 114(2). 211–221. 15 indexed citations
10.
Bernard‐Pierrot, Isabelle, Andrew Cassidy, Alexander Graham, et al.. (2004). Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. Oncogene. 23(57). 9201–9211. 35 indexed citations
11.
Duggan, Catherine, Susan Kennedy, Chad A. Barnes, et al.. (1997). Plasminogen activator inhibitor type 2 in breast cancer. British Journal of Cancer. 76(5). 622–627. 60 indexed citations
12.
Lindmark, G, Wolfgang Kraaz, Paul Elvin, & Bengt Glimelius. (1997). Rectal cancer: evaluation of staging with endosonography.. Radiology. 204(2). 533–538. 18 indexed citations
13.
Elvin, Paul, et al.. (1995). Induction of apoptosis by anti-cancer drugs with disparate modes of action: kinetics of cell death and changes in c-myc expression. British Journal of Cancer. 71(5). 937–941. 29 indexed citations
14.
Butler, Rachel, Donald Ogilvie, Paul Elvin, et al.. (1992). Walking, cloning, and mapping with yeast artificial chromosomes: A contig encompassing D21S13 and D21S16. Genomics. 12(1). 42–51. 11 indexed citations
15.
Harvie, Rozelle, et al.. (1991). Detection of mRNA for ribosomal phosphoprotein P2 in normal colon and colonic tumours by In situ hybridization. The Journal of Pathology. 164(1). 67–73. 4 indexed citations
16.
Heath, Paul R., et al.. (1990). Localisation of a cDNA clone for human cytokeratin 18 to chromosome 17p11?p12 by in situ hybridisation. Human Genetics. 85(6). 669–70. 5 indexed citations
17.
Elvin, Paul, D. N. Black, Alexander Graham, et al.. (1990). Isolation of cDNA clones using yeast artificial chromosome probes. Nucleic Acids Research. 18(13). 3913–3917. 67 indexed citations
18.
Elvin, Paul, et al.. (1990). A sequence previously identified as metastasis-related encodes an acidic ribosomal phosphoprotein, P2. British Journal of Cancer. 61(1). 83–88. 33 indexed citations
19.
20.
Elvin, Paul & Clive W. Evans. (1985). Adhesive properties of the B16 melanoma.. PubMed. 172A. 537–47. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven A. Enkemann Breakdown of academic impact, for papers by Dorina Gui Breakdown of academic impact, for papers by Hoanh Tran Breakdown of academic impact, for papers by Pjotr Knyazev Breakdown of academic impact, for papers by Maria Zajac‐Kaye Breakdown of academic impact, for papers by Sachi Horibata Breakdown of academic impact, for papers by Mei Dong Breakdown of academic impact, for papers by Mariana Nacht Breakdown of academic impact, for papers by Wendy S. Halsey Breakdown of academic impact, for papers by Randolph S. Watnick
Rankless by CCL
2026